Study details
Enrolling now
Phage Treatment for Cystic Fibrosis Lung Infection
BiomX Ltd
NCT IDNCT06998043ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
63
Study length
about 1.2 years
Ages
18+
Locations
14 sites in AK, AL, AR +7
About this study
Researchers are testing whether nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa lung infection in people with cystic fibrosis. The trial will last 455 days and involve comparing BX004 to a placebo, along with their usual CF treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Receive BX004
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Change from Baseline in CFQ-R respiratory domain, Change from Baseline in CFRSD-CRISS, Incidence of treatment-emergent adverse events [safety and tolerability]
Body systems
Infectious, Respiratory